BioNTech (BNTX) Competitors

BioNTech logo
$80.77 -0.61 (-0.75%)
Closing price 11/20/2026 03:58 PM Eastern
Extended Trading
$81.50 +0.73 (+0.90%)
As of 11/20/2026 07:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BNTX vs. ARGX, NTRA, RVMD, BIIB, and GMAB

Should you buy BioNTech stock or one of its competitors? BioNTech's main competitors and comparable companies include argenex (ARGX), Natera (NTRA), Revolution Medicines (RVMD), Biogen (BIIB), and Genmab A/S (GMAB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does BioNTech compare to argenex?

argenex (NASDAQ:ARGX) and BioNTech (NASDAQ:BNTX) are both large-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, earnings, institutional ownership, media sentiment and dividends.

argenex currently has a consensus target price of $1,163.18, indicating a potential upside of 25.70%. BioNTech has a consensus target price of $120.44, indicating a potential upside of 49.11%. Given BioNTech's higher probable upside, analysts plainly believe BioNTech is more favorable than argenex.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
argenex
0 Sell rating(s)
6 Hold rating(s)
21 Buy rating(s)
1 Strong Buy rating(s)
2.82
BioNTech
1 Sell rating(s)
6 Hold rating(s)
12 Buy rating(s)
1 Strong Buy rating(s)
2.65

In the previous week, BioNTech had 2 more articles in the media than argenex. MarketBeat recorded 6 mentions for BioNTech and 4 mentions for argenex. BioNTech's average media sentiment score of 0.99 beat argenex's score of 0.26 indicating that BioNTech is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
argenex
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
BioNTech
3 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

argenex has a beta of 0.48, indicating that its share price is 52% less volatile than the broader market. Comparatively, BioNTech has a beta of 1.28, indicating that its share price is 28% more volatile than the broader market.

60.3% of argenex shares are held by institutional investors. Comparatively, 15.5% of BioNTech shares are held by institutional investors. 2.4% of argenex shares are held by insiders. Comparatively, 19.2% of BioNTech shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

argenex has a net margin of 31.66% compared to BioNTech's net margin of -61.39%. argenex's return on equity of 47.70% beat BioNTech's return on equity.

Company Net Margins Return on Equity Return on Assets
argenex31.66% 47.70% 40.12%
BioNTech -61.39%-4.51%-3.96%

argenex has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
argenex$4.25B13.70$1.29B$28.6632.29
BioNTech$3.25B6.29-$1.29B-$6.85N/A

Summary

argenex beats BioNTech on 11 of the 16 factors compared between the two stocks.

How does BioNTech compare to Natera?

BioNTech (NASDAQ:BNTX) and Natera (NASDAQ:NTRA) are both large-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation, analyst recommendations and media sentiment.

15.5% of BioNTech shares are owned by institutional investors. Comparatively, 99.9% of Natera shares are owned by institutional investors. 19.2% of BioNTech shares are owned by company insiders. Comparatively, 5.1% of Natera shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

BioNTech presently has a consensus target price of $120.44, suggesting a potential upside of 49.11%. Natera has a consensus target price of $396.93, suggesting a potential upside of 45.35%. Given BioNTech's higher possible upside, analysts clearly believe BioNTech is more favorable than Natera.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioNTech
1 Sell rating(s)
6 Hold rating(s)
12 Buy rating(s)
1 Strong Buy rating(s)
2.65
Natera
2 Sell rating(s)
2 Hold rating(s)
17 Buy rating(s)
2 Strong Buy rating(s)
2.83

In the previous week, Natera had 1 more articles in the media than BioNTech. MarketBeat recorded 7 mentions for Natera and 6 mentions for BioNTech. BioNTech's average media sentiment score of 0.99 beat Natera's score of 0.13 indicating that BioNTech is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BioNTech
3 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Natera
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
2 Negative mention(s)
1 Very Negative mention(s)
Neutral

Natera has lower revenue, but higher earnings than BioNTech. Natera is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioNTech$3.25B6.29-$1.29B-$6.85N/A
Natera$2.31B17.17-$208.16M-$1.14N/A

BioNTech has a beta of 1.28, suggesting that its share price is 28% more volatile than the broader market. Comparatively, Natera has a beta of 1.55, suggesting that its share price is 55% more volatile than the broader market.

Natera has a net margin of -5.66% compared to BioNTech's net margin of -61.39%. BioNTech's return on equity of -4.51% beat Natera's return on equity.

Company Net Margins Return on Equity Return on Assets
BioNTech-61.39% -4.51% -3.96%
Natera -5.66%-8.61%-5.93%

Summary

Natera beats BioNTech on 10 of the 17 factors compared between the two stocks.

How does BioNTech compare to Revolution Medicines?

Revolution Medicines (NASDAQ:RVMD) and BioNTech (NASDAQ:BNTX) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.

In the previous week, Revolution Medicines had 20 more articles in the media than BioNTech. MarketBeat recorded 26 mentions for Revolution Medicines and 6 mentions for BioNTech. BioNTech's average media sentiment score of 0.99 beat Revolution Medicines' score of 0.51 indicating that BioNTech is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Revolution Medicines
8 Very Positive mention(s)
4 Positive mention(s)
12 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
BioNTech
3 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Revolution Medicines has higher earnings, but lower revenue than BioNTech. Revolution Medicines is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Revolution Medicines$197.56M175.86-$1.13B-$9.11N/A
BioNTech$3.25B6.29-$1.29B-$6.85N/A

Revolution Medicines has a net margin of 0.00% compared to BioNTech's net margin of -61.39%. BioNTech's return on equity of -4.51% beat Revolution Medicines' return on equity.

Company Net Margins Return on Equity Return on Assets
Revolution MedicinesN/A -84.51% -51.97%
BioNTech -61.39%-4.51%-3.96%

Revolution Medicines currently has a consensus price target of $262.75, suggesting a potential upside of 63.57%. BioNTech has a consensus price target of $120.44, suggesting a potential upside of 49.11%. Given Revolution Medicines' stronger consensus rating and higher possible upside, research analysts clearly believe Revolution Medicines is more favorable than BioNTech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Revolution Medicines
1 Sell rating(s)
1 Hold rating(s)
21 Buy rating(s)
1 Strong Buy rating(s)
2.92
BioNTech
1 Sell rating(s)
6 Hold rating(s)
12 Buy rating(s)
1 Strong Buy rating(s)
2.65

Revolution Medicines has a beta of 1.44, meaning that its share price is 44% more volatile than the broader market. Comparatively, BioNTech has a beta of 1.28, meaning that its share price is 28% more volatile than the broader market.

94.3% of Revolution Medicines shares are owned by institutional investors. Comparatively, 15.5% of BioNTech shares are owned by institutional investors. 7.6% of Revolution Medicines shares are owned by insiders. Comparatively, 19.2% of BioNTech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Revolution Medicines beats BioNTech on 9 of the 16 factors compared between the two stocks.

How does BioNTech compare to Biogen?

Biogen (NASDAQ:BIIB) and BioNTech (NASDAQ:BNTX) are both large-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Biogen presently has a consensus target price of $255.45, suggesting a potential upside of 2.35%. BioNTech has a consensus target price of $120.44, suggesting a potential upside of 49.11%. Given BioNTech's higher possible upside, analysts plainly believe BioNTech is more favorable than Biogen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biogen
1 Sell rating(s)
10 Hold rating(s)
21 Buy rating(s)
1 Strong Buy rating(s)
2.67
BioNTech
1 Sell rating(s)
6 Hold rating(s)
12 Buy rating(s)
1 Strong Buy rating(s)
2.65

Biogen has a beta of 0.1, indicating that its stock price is 90% less volatile than the broader market. Comparatively, BioNTech has a beta of 1.28, indicating that its stock price is 28% more volatile than the broader market.

Biogen has a net margin of 3.37% compared to BioNTech's net margin of -61.39%. Biogen's return on equity of 9.38% beat BioNTech's return on equity.

Company Net Margins Return on Equity Return on Assets
Biogen3.37% 9.38% 5.69%
BioNTech -61.39%-4.51%-3.96%

87.9% of Biogen shares are owned by institutional investors. Comparatively, 15.5% of BioNTech shares are owned by institutional investors. 0.3% of Biogen shares are owned by company insiders. Comparatively, 19.2% of BioNTech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Biogen had 43 more articles in the media than BioNTech. MarketBeat recorded 49 mentions for Biogen and 6 mentions for BioNTech. BioNTech's average media sentiment score of 0.99 beat Biogen's score of 0.75 indicating that BioNTech is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Biogen
22 Very Positive mention(s)
6 Positive mention(s)
15 Neutral mention(s)
4 Negative mention(s)
1 Very Negative mention(s)
Positive
BioNTech
3 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Biogen has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biogen$9.89B3.73$1.29B$2.34106.66
BioNTech$3.25B6.29-$1.29B-$6.85N/A

Summary

Biogen beats BioNTech on 11 of the 16 factors compared between the two stocks.

How does BioNTech compare to Genmab A/S?

Genmab A/S (NASDAQ:GMAB) and BioNTech (NASDAQ:BNTX) are both large-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends.

Genmab A/S currently has a consensus price target of $53.50, suggesting a potential upside of 5.90%. BioNTech has a consensus price target of $120.44, suggesting a potential upside of 49.11%. Given BioNTech's higher possible upside, analysts clearly believe BioNTech is more favorable than Genmab A/S.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Genmab A/S
0 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
3.00
BioNTech
1 Sell rating(s)
6 Hold rating(s)
12 Buy rating(s)
1 Strong Buy rating(s)
2.65

In the previous week, Genmab A/S and Genmab A/S both had 6 articles in the media. BioNTech's average media sentiment score of 0.99 beat Genmab A/S's score of 0.75 indicating that BioNTech is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Genmab A/S
3 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
BioNTech
3 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

7.1% of Genmab A/S shares are held by institutional investors. Comparatively, 15.5% of BioNTech shares are held by institutional investors. 1.5% of Genmab A/S shares are held by company insiders. Comparatively, 19.2% of BioNTech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Genmab A/S has a beta of 0.73, suggesting that its stock price is 27% less volatile than the broader market. Comparatively, BioNTech has a beta of 1.28, suggesting that its stock price is 28% more volatile than the broader market.

Genmab A/S has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genmab A/S$3.72B8.48$963M$1.1743.18
BioNTech$3.25B6.29-$1.29B-$6.85N/A

Genmab A/S has a net margin of 16.97% compared to BioNTech's net margin of -61.39%. Genmab A/S's return on equity of 13.67% beat BioNTech's return on equity.

Company Net Margins Return on Equity Return on Assets
Genmab A/S16.97% 13.67% 6.42%
BioNTech -61.39%-4.51%-3.96%

Summary

Genmab A/S beats BioNTech on 9 of the 15 factors compared between the two stocks.

Get BioNTech News Delivered to You Automatically

Sign up to receive the latest news and ratings for BNTX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BNTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BNTX vs. The Competition

MetricBioNTechBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$20.47B$3.92B$7.44B$10.86B
Dividend YieldN/A3.79%2.51%4.60%
P/E Ratio-11.7923.0732.5628.68
Price / Sales8.4414.847.815.19
Price / Cash60.6421.9220.2520.77
Price / Book1.004.124.343.51
Net Income-$1.29B-$24.08M$3.51B$394.12M
7 Day Performance-5.64%-9.85%-8.07%-8.97%
1 Month Performance-9.92%-12.77%-10.29%-11.61%
1 Year Performance-15.50%-7.99%-4.70%-11.21%

BioNTech Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BNTX
BioNTech
3.6506 of 5 stars
$80.77
-0.7%
$120.44
+49.1%
-15.5%$20.47B$2.42BN/A7,807
ARGX
argenex
4.5383 of 5 stars
$950.95
-0.9%
$1,163.18
+22.3%
+0.7%$61.71B$4.25B33.181,863
NTRA
Natera
2.8334 of 5 stars
$288.48
-9.6%
$394.31
+36.7%
+18.4%$46.83B$2.31BN/A6,140
RVMD
Revolution Medicines
3.2488 of 5 stars
$166.87
-3.1%
$262.75
+57.5%
+126.7%$38.14B$11.58MN/A883
BIIB
Biogen
2.904 of 5 stars
$251.65
-0.7%
$254.41
+1.1%
+42.4%$37.03B$9.89B21.267,500

Related Companies and Tools


This page (NASDAQ:BNTX) was last updated on 11/22/2026 by MarketBeat.com Staff.
From Our Partners